TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GSK PLC Stock

Certificat

DE000CL5LG77

Market Closed - Deutsche Boerse AG 03:46:32 2024-07-04 pm EDT
4.69 EUR +2.63% Intraday chart for TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GSK PLC
Current month-3.50%
1 month-21.04%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart GSK PLC
Chart TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GSK PLC
Date Price Change
24-07-04 4.69 +2.63%
24-07-03 4.57 -0.22%
24-07-02 4.58 -5.37%
24-07-01 4.84 -0.41%
24-06-28 4.86 -0.82%

Delayed Quote Deutsche Boerse AG

Last update July 04, 2024 at 03:46 pm EDT

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying GSK PLC
IssuerLogo Issuer Société Générale Société Générale
WKN CL5LG7
ISINDE000CL5LG77
Date issued 2020-03-18
Strike 1,118 p
Maturity Unlimited
Parity 1 : 1
Emission price 3.61
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 9.42
Lowest since issue 2.01
Spread 0.13
Spread %2.70%

Company Profile

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Sector
-
More about the company

Ratings for GSK plc

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: GSK plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
15.1 GBP
Average target price
20.28 GBP
Spread / Average Target
+34.23%
Consensus